期刊簡介 | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | BLOOD CELLS MOLECULES AND DISEASES LetPub Score 5.5
50 ratings
Rate
Reputation 6.4 Influence 3.9 Speed 9.7 | ||||||||||||||||||||||||||||
期刊簡稱 | BLOOD CELL MOL DIS | ||||||||||||||||||||||||||||
ISSN | 1079-9796 | ||||||||||||||||||||||||||||
E-ISSN | 1096-0961 | ||||||||||||||||||||||||||||
h-index | 82 | ||||||||||||||||||||||||||||
CiteScore |
| ||||||||||||||||||||||||||||
自引率 (2023-2024) | 4.80%自引率趨勢 | ||||||||||||||||||||||||||||
掲載範囲 |
| ||||||||||||||||||||||||||||
官方網站 | http://www.journals.elsevier.com/blood-cells-molecules-and-diseases/ | ||||||||||||||||||||||||||||
在線稿件提交 | http://ees.elsevier.com/bcmd/default.asp?pg=login.asp | ||||||||||||||||||||||||||||
開放訪問 | No | ||||||||||||||||||||||||||||
出版商 | Academic Press Inc. | ||||||||||||||||||||||||||||
主題領域 | 医学 | ||||||||||||||||||||||||||||
出版國/地區 | UNITED STATES | ||||||||||||||||||||||||||||
發行頻率 | 隔月刊行 | ||||||||||||||||||||||||||||
創刊年 | 1995 | ||||||||||||||||||||||||||||
每年文章數 | 31每年文章數趨勢 | ||||||||||||||||||||||||||||
黃金OA百分比 | 12.70% | ||||||||||||||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q3
| ||||||||||||||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Science Citation Index Expanded | ||||||||||||||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1079-9796%5BISSN%5D | ||||||||||||||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Slow, 6-12 Week(s) | ||||||||||||||||||||||||||||
競爭力 * | 來自作者的數據: Moderate | ||||||||||||||||||||||||||||
在線文章發布時間 | 來自Elsevier的數據: Average 5.8 Week(s) | ||||||||||||||||||||||||||||
參考鏈接 |
| ||||||||||||||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
首頁 上一頁 1 下一頁 末頁 (頁 | |
[BLOOD CELLS MOLECULES AND DISEASES] 的評論 | 撰寫評論 |
作者: 兰花涵亦 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2024-02-15 21:41:00 評論於 Is it okay to submit submissions now? How long is the submission period?(0) 讚! | 兰花涵亦 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 22:50:57 評論於 The method of relative quantification in qPCR is the ΔΔCT method, first calibrating with a reference gene, and then calculating the difference between the sample and control groups(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 09:19:05 評論於 Please translate the following paragraph into English and Japanese, with titles ":" and ":"(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 龙鳞孝礼 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-28 18:30:33 評論於 How to handle the results of qPCR?(0) 讚! | 龙鳞孝礼 |
作者: Darlene Pepys 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-28 16:18:02 評論於 Can my search results include video results?(0) 讚! | Darlene Pepys |
作者: 蚀骨香芹 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2019-03-25 08:37:46 評論於 What direction are you in?(0) 讚! | 蚀骨香芹 |
作者: Eilis 領域: 医学 審稿時間: 3.0 month(s) 結果: 修改後接受 撰寫評論 |
2018-11-23 17:47:09 評論於 Although this journal was quite good years ago, it has become worse and worse in recent years. Reconsider submitting. (0) 讚! | Eilis |
作者: 凌霄秀梅 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2018-11-23 16:06:17 評論於 Review Speed: 1.0 | Submission Hit Rate: 75.0 Sharing Experience: It was pretty good before, but it's been getting worse in recent years. Could it drop to Zone 4?(0) 讚! | 凌霄秀梅 |
作者: 璃沙依冬 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-08-06 10:45:07 評論於 Are you still accepting case reports?(0) 讚! | 璃沙依冬 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-07-18 14:43:39 評論於 Damn it, last year I scored over 2 points for an article I published, but this year it's just over 1 point. Will it drop even further next year? Who would want to invest in it?!(0) 讚! | 凌霄高洁 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-07-18 13:55:01 評論於 Too harsh! After such a big drop, who dare to invest in the future??(0) 讚! | 凌霄高洁 |
作者: Cara Howells 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2016-10-31 15:24:54 評論於 Review speed: 1.0 | Submission hit rate: 50.0 Experience sharing: I have submitted to this journal twice this year. The first time, my case report was instantly rejected because the journal no longer accepts case reports. The second time, I submitted on October 8, 2016, and the status was "with editor" until October 30, when it suddenly changed to "accept." I couldn't believe it, it was accepted without being sent out for review. I thought the editor was on vacation, but they accepted it directly. The speed was really fast(0) 讚! | Cara Howells |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2015-08-22 10:26:35 評論於 Review Speed: 1.0 Experience Sharing: Before submitting my article, I read several similar articles in this journal and felt that my article was at least better than those. I submitted it in less than a month, but it was sent to a different reviewer midway and ultimately rejected. That's fine, I can accept that my level wasn't good enough. However, the rejection comments were just terrible. It was clear that the reviewer didn't understand the article at all and misinterpreted the issues mentioned. Most of the comments were about not understanding certain sentences or finding contradictions, but did the reviewer actually read the article carefully? They started by saying my article was poorly written and several parts didn't make sense. There wasn't a single valuable suggestion. My article wasn't submitted as is, both my boss and I had already made revisions to it, so there shouldn't have been any language issues as bad as "poorly written," right? And the editor was also irresponsible for accepting such terrible review comments without giving a chance for corrections. I assume the reviewer just passed my article on to a student or someone, who also didn't bother to make changes and just rejected it with a few random comments. It's really disappointing! I hope this is just an isolated case(0) 讚! | 凌霄高洁 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2013-10-29 23:46:21 評論於 I have submitted an article before, but it was rejected(0) 讚! | 凌霄高洁 |
首頁 上一頁 1 下一頁 末頁 (頁 |
Contact us